

Prurigo nodularis – Pipeline Insight, 2020

<https://marketpublishers.com/r/P67E7C385944EN.html>

Date: September 2020

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P67E7C385944EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Prurigo nodularis – Pipeline Insight, 2020," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prurigo nodularis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Prurigo nodularis Understanding

Prurigo nodularis: Overview

Prurigo nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin. The itching (pruritus) can be intense, causing people to scratch themselves to the point of bleeding or pain. Scratching can cause more skin lesions to appear. The itching is worsened by heat, sweating, or irritation from clothing.[4] In some cases, people with PN have a history of other diseases including eczema (atopic dermatitis), lymphoma, HIV infection, severe anemia, or kidney disease.

The exact cause of PN is unknown. Although scratching is known to cause more nodules to appear, it is unclear what causes the itching to develop in the first place.

Symptoms

The main symptom of prurigo nodularis (PN) is the formation of hard, very itchy lumps (nodules) on the skin. The nodules can range in size from very small to about half an inch in diameter. The nodules often have a rough, dry top and can range in number from a few to hundreds. Nodules most commonly form on the outer arms, shoulders, and legs. Nodules can also form on the neck and trunk, and they rarely form on the face and palms. They may be lighter or darker in color than the surrounding skin. Scarring may occur after nodules begin to heal.

Diagnosis

Prurigo nodularis may be suspected when a person has signs and symptoms of the disease including intensely itchy skin and the development of nodules on the skin. In some cases, a doctor may wish to perform a skin biopsy to look for signs of the disease such as thickened nerves in the skin. After the diagnosis has been confirmed, other tests such as a blood test and tests of liver and kidney function may be recommended to rule out underlying causes of the disease.

Treatment

Prurigo nodularis (PN) can be challenging to treat because people with the disease may respond to treatments differently. Due to the intensity of the itch, people with PN may try several different treatments without receiving much relief. Some people may try all current treatments available without receiving complete relief. For most people, a combination of several treatments may need to be tried to find out what will work best.

The most commonly used treatments for PN are:

- Corticosteroid creams that are applied to the nodules (topical) and covered with special bandages that are air- and water-tight

- Corticosteroid injections into the nodules

- Ointments with menthol or phenol to cool and soothe itchy skin

- Capsaicin cream

- Oral corticosteroids

Oral antihistamines

Selective serotonin reuptake inhibitors (SSRIs)

Prurigo nodularis Emerging Drugs Chapters

This segment of the Prurigo nodularis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Prurigo nodularis Emerging Drugs

Nemolizumab: Chugai/Galderma

Nemolizumab was discovered by Chugai, and uses Chugai's proprietary antibody engineering technology ACT-Ig, which can extend the biological half-life of antibodies in blood. IL-31 has been identified as a pruritogenic cytokine, and reported to be associated with pruritus in many diseases including atopic dermatitis and hemodialysis. Nemolizumab is designed to inhibit the activities of IL-31 by competitively blocking binding with its receptor. It is currently in phase III stage of development.

Nalbuphine ER: Trevi Therapeutics

Trevi is developing nalbuphine ER in a range of indications for which patients have few treatment options. With its dual mechanism of action, acting as both an antagonist (blocker) to the mu opioid receptor and as an agonist (activator) to the kappa opioid receptor, Nalbuphine ER has the potential to significantly improve the quality of life of patients suffering from serious neurologically mediated conditions by targeting the central and peripheral nervous systems. It is currently in phase III stage of development.

Vixarelimab: Kiniksa Pharmaceuticals

Vixarelimab is Monoclonal antibody inhibiting signaling through oncostatin M receptor

beta (OSMR?). Vixarelimab inhibits signaling of interleukin-31 (IL-31) and oncostatin M (OSM), 2 key cytokines implicated in inflammation, pruritus, and fibrosis. It is currently in phase II stage of development.

Further product details are provided in the report

Prurigo nodularis: Therapeutic Assessment

This segment of the report provides insights about the different Prurigo nodularis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Prurigo nodularis

There are approx. 5+ key companies which are developing the therapies for Prurigo nodularis. The companies which have their Prurigo nodularis drug candidates in the most advanced stage, i.e. phase III include Chugai/Galderma and others

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Prurigo nodularis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various

ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravenous

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Gene therapies

Small molecule

Vaccines

Polymers

Peptides

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Prurigo nodularis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Prurigo nodularis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prurigo nodularis drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Prurigo nodularis R&D. The therapies under development are focused on novel approaches to treat/improve Prurigo nodularis.

In July 2016, Chugai Pharmaceutical and Galderma Pharma S.A. announced that they have entered into a global license agreement for “nemolizumab” (CIM331). Under the agreement, Chugai will grant Galderma an exclusive license for the development and marketing of nemolizumab worldwide, with the exception of Japan and Taiwan.

In April 2020, Kiniksa Pharmaceuticals announced data from the phase IIa clinical trial in prurigo nodularis for vixarelimab (KPL-716). The trial met its primary efficacy endpoint: the reduction in weekly-average WI-NRS from baseline at Week 8 was statistically significantly greater in patients who received vixarelimab versus those who received placebo.

Prurigo nodularis Report Insights

Prurigo nodularis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Prurigo nodularis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Prurigo nodularis drugs?

How many Prurigo nodularis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prurigo nodularis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Prurigo nodularis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Prurigo nodularis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Menlo Therapeutics

Galderma R&D

Kiniksa Pharmaceuticals

Sanofi

Maruho

Key Products

Serlopitant

Nemolizumab

KPL-716

SAR231893

M118103

Contents

Introduction

Executive Summary

Prurigo nodularis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Prurigo nodularis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Prurigo nodularis companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Prurigo nodularis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Nemolizumab: Chugai/Galderma

Product Description

Research and Development

Product Development Activities

Nalbuphine ER: Trevi Therapeutics

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

Vixarelimab: Kiniksa Pharmaceuticals

- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- Drug Name: Company Name
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products
 - Comparative Analysis
- Drug Name: Company Name
 - Product Description
 - Research and Development
 - Product Development Activities
- Inactive Products
 - Comparative Analysis
- Prurigo nodularis Key Companies
- Prurigo nodularis Key Products
- Prurigo nodularis- Unmet Needs
- Prurigo nodularis- Market Drivers and Barriers
- Prurigo nodularis- Future Perspectives and Conclusion
- Prurigo nodularis Analyst Views
- Prurigo nodularis Key Companies
- Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Prurigo nodularis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Prurigo nodularis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Prurigo nodularis – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/P67E7C385944EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P67E7C385944EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970